Cargando…
OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model
Spike-based COVID-19 vaccines induce potent neutralizing antibodies but their efficacy against SARS-CoV-2 variants decreases. OVX033 is a recombinant protein composed of the full-length nucleocapsid (N) protein of SARS-CoV-2 genetically fused to oligoDOM(®), a self-assembling domain which improves a...
Autores principales: | Primard, Charlotte, Monchâtre-Leroy, Elodie, Del Campo, Judith, Valsesia, Séverine, Nikly, Elsa, Chevandier, Marion, Boué, Franck, Servat, Alexandre, Wasniewski, Marine, Picard-Meyer, Evelyne, Courant, Thomas, Collin, Nicolas, Salguero, Francisco J., Le Vert, Alexandre, Guyon-Gellin, Delphine, Nicolas, Florence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319154/ https://www.ncbi.nlm.nih.gov/pubmed/37409116 http://dx.doi.org/10.3389/fimmu.2023.1188605 |
Ejemplares similares
-
372. Co-Administration of OVX836, NP-Based Universal Influenza Vaccine Candidate, with Conventional HA-Based Influenza Vaccine: Results of Phase 2a Clinical trial
por: Willems, Paul, et al.
Publicado: (2023) -
OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza
por: Del Campo, Judith, et al.
Publicado: (2021) -
Hamster and ferret experimental infection with intranasal low dose of a single strain of SARS-CoV-2
por: Monchatre-Leroy, Elodie, et al.
Publicado: (2021) -
Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model
por: Bessière, Pierre, et al.
Publicado: (2021) -
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results( )
por: Withanage, Kanchanamala, et al.
Publicado: (2021)